CONTEXT: Metformin therapy for adults and children with type 2 diabetes is well established. However, its role in the treatment of insulin resistance and obesity in children and adolescents is less clearly defined. OBJECTIVE: We assessed the effect of metformin on body composition and insulin sensitivity in pediatric subjects with exogenous obesity. DESIGN AND SETTING:Patients referred to a pediatric endocrine clinic were enrolled in a randomized, double-blind, crossover trial. PATIENTS: Twenty-eight patients (13 males) aged 9-18 yr participated in the study. INTERVENTION: Patients received metformin (1 g twice daily) and placebo for 6 months, each with a 2-wk washout period. MAIN OUTCOME MEASURES: Body composition (anthropometry, dual-energy x-ray absorptiometry, and abdominal magnetic resonance imaging), and insulin sensitivity (Si; minimal model, fasting insulin and glucose) were measured at baseline and 6 and 12 months. RESULTS:Mean age of subjects at baseline was 12.5 +/- 2.2 yr, median body mass index z-score 2.54 (range, 1.93-2.85). Metformin had a greater treatment effect over placebo for weight (-4.35 kg, P = 0.02), body mass index (-1.26 kg/m(2), P = 0.002), waist circumference (-2.8 cm, P = 0.003), sc abdominal adipose tissue (-52.5 cm(2), P = 0.002), and fasting insulin (-2.2 mU/liter, P = 0.011). Si improved in 45% of subjects while on metformin and 27% of subjects while on placebo (P = 0.21). CONCLUSIONS:Metformin therapy for obese insulin-resistant pediatric patients results in significant improvement in body composition and fasting insulin. Although improvement in Si was noted in many individuals, Si was a less useful parameter for analysis of group data, possibly because of effects of variable compliance and changing Si during puberty.
RCT Entities:
CONTEXT: Metformin therapy for adults and children with type 2 diabetes is well established. However, its role in the treatment of insulin resistance and obesity in children and adolescents is less clearly defined. OBJECTIVE: We assessed the effect of metformin on body composition and insulin sensitivity in pediatric subjects with exogenous obesity. DESIGN AND SETTING:Patients referred to a pediatric endocrine clinic were enrolled in a randomized, double-blind, crossover trial. PATIENTS: Twenty-eight patients (13 males) aged 9-18 yr participated in the study. INTERVENTION: Patients received metformin (1 g twice daily) and placebo for 6 months, each with a 2-wk washout period. MAIN OUTCOME MEASURES: Body composition (anthropometry, dual-energy x-ray absorptiometry, and abdominal magnetic resonance imaging), and insulin sensitivity (Si; minimal model, fasting insulin and glucose) were measured at baseline and 6 and 12 months. RESULTS: Mean age of subjects at baseline was 12.5 +/- 2.2 yr, median body mass index z-score 2.54 (range, 1.93-2.85). Metformin had a greater treatment effect over placebo for weight (-4.35 kg, P = 0.02), body mass index (-1.26 kg/m(2), P = 0.002), waist circumference (-2.8 cm, P = 0.003), sc abdominal adipose tissue (-52.5 cm(2), P = 0.002), and fasting insulin (-2.2 mU/liter, P = 0.011). Si improved in 45% of subjects while on metformin and 27% of subjects while on placebo (P = 0.21). CONCLUSIONS:Metformin therapy for obese insulin-resistant pediatric patients results in significant improvement in body composition and fasting insulin. Although improvement in Si was noted in many individuals, Si was a less useful parameter for analysis of group data, possibly because of effects of variable compliance and changing Si during puberty.
Authors: Wai Johnn Sam; Orsolya Roza; Yuen Yi Hon; Raul M Alfaro; Karim A Calis; James C Reynolds; Jack A Yanovski Journal: J Clin Pharmacol Date: 2016-08-23 Impact factor: 3.126
Authors: M A Adeyemo; J R McDuffie; M Kozlosky; J Krakoff; K A Calis; S M Brady; J A Yanovski Journal: Diabetes Obes Metab Date: 2015-01-11 Impact factor: 6.577
Authors: Zhihong Gong; Aaron K Aragaki; Rowan T Chlebowski; JoAnn E Manson; Thomas E Rohan; Chu Chen; Mara Z Vitolins; Lesley F Tinker; Erin S LeBlanc; Lewis H Kuller; Lifang Hou; Michael J LaMonte; Juhua Luo; Jean Wactawski-Wende Journal: Int J Cancer Date: 2015-12-15 Impact factor: 7.396
Authors: Cheril L Clarson; Farid H Mahmud; Janet E Baker; Helen E Clark; Wendy M McKay; Vicki D Schauteet; David J Hill Journal: Endocrine Date: 2009-04-23 Impact factor: 3.633
Authors: A Justine Wilson; Harry Prapavessis; Mary E Jung; Anita G Cramp; Joy Vascotto; Larissa Lenhardt; J Kevin Shoemaker; Margaret Watson; Tracy Robinson; Cheril L Clarson Journal: BMC Public Health Date: 2009-11-30 Impact factor: 3.295